Batoclimab

Summary

Batoclimab (CHEMBL4650514) is a phase-3 clinical-stage antibody targeting FCGRT; indicated across 9 conditions including myasthenia gravis and autoimmune thrombocytopenic purpura.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (FCGRT)
• Indications: 9 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650514
Name	Batoclimab
Type	Antibody
Max phase	3

Also known as: Batoclimab, HBM-9161, HBM9161, HL161BKN, Rvt-1401, RVT-1401, RVT1401, BATOCLIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
FCGRT	Fc fragment of IgG receptor and transporter	Binding		0%	P55899

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): FCGRT.

Dominant GO biological processes

GO term	Targets
IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor	1
immune response	1

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myasthenia gravis	3	MONDO:0009688	EFO:0004991
autoimmune thrombocytopenic purpura	2	MONDO:0008558	EFO:0007160
autoimmune hemolytic anemia	2	MONDO:0020108	EFO:1001264
Graves disease	2	MONDO:0005364	EFO:0004237
Guillain-Barre syndrome, familial	2	MONDO:0007691	EFO:0009538
neuromyelitis optica	1	MONDO:0019100	EFO:0004256
autoimmune disease	1	MONDO:0007179	EFO:0005809
pemphigus	1	MONDO:0006594	EFO:1000749

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05517421	PHASE3	COMPLETED	Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
NCT05517447	PHASE3	TERMINATED	Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
NCT05524571	PHASE3	COMPLETED	Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
NCT05581199	PHASE2	ACTIVE_NOT_RECRUITING	To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
NCT07188844	PHASE2	ENROLLING_BY_INVITATION	An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT03863080	PHASE2	COMPLETED	A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
NCT03922321	PHASE2	COMPLETED	Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves’ Ophthalmopathy (GO)
NCT04253236	PHASE2	TERMINATED	To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
NCT04227470	PHASE1	COMPLETED	A Study of HBM9161 in NMOSD Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).